Univest Of Pennsylvania Decreased Abbvie (ABBV) Position By $578,688; QT VASCULAR LTD. ORDINARY SHARES SINGAP (QTVLF) Shorts Raised By 73.79%

March 18, 2018 - By Linda Rogers

Univest Corp Of Pennsylvania decreased Abbvie Inc (ABBV) stake by 11.2% reported in 2017Q3 SEC filing. Univest Corp Of Pennsylvania sold 6,576 shares as Abbvie Inc (ABBV)’s stock rose 6.17%. The Univest Corp Of Pennsylvania holds 52,160 shares with $4.64 million value, down from 58,736 last quarter. Abbvie Inc now has $180.57 billion valuation. The stock decreased 1.06% or $1.22 during the last trading session, reaching $113.71. About 8.88 million shares traded or 44.91% up from the average. AbbVie Inc. (NYSE:ABBV) has risen 10.63% since March 18, 2017 and is uptrending. It has underperformed by 6.07% the S&P500.

QT VASCULAR LTD. ORDINARY SHARES SINGAP (OTCMKTS:QTVLF) had an increase of 73.79% in short interest. QTVLF’s SI was 104,100 shares in March as released by FINRA. Its up 73.79% from 59,900 shares previously. With 245,800 avg volume, 0 days are for QT VASCULAR LTD. ORDINARY SHARES SINGAP (OTCMKTS:QTVLF)’s short sellers to cover QTVLF’s short positions. The SI to QT VASCULAR LTD. ORDINARY SHARES SINGAP’s float is 0.01%. It closed at $0.0159 lastly. It is down 0.00% since March 18, 2017 and is . It has underperformed by 16.70% the S&P500.

QT Vascular Ltd., together with its subsidiaries, designs, assembles, and distributes therapeutic solutions for the minimally invasive treatment of complex vascular diseases. The company has market cap of $36.61 million. The firm offers coronary products, including Chocolate percutaneous transluminal coronary angioplasty balloon catheter to reduce vessel trauma by providing balloon inflation; and Glider PTCA for the treatment of various complex lesions. It currently has negative earnings. It also provides Chocolate percutaneous transluminal angioplasty (PTA) balloon catheter for the treatment of blocked arteries; Chocolate Touch, a drug-coated balloon catheter; GliderfleX PTA for treating distal peripheral vessels; and GliderXtreme PTA balloon catheter that targets complex lesions in the distal peripheral vasculature.

Investors sentiment decreased to 0.8 in Q3 2017. Its down 0.05, from 0.85 in 2017Q2. It worsened, as 55 investors sold ABBV shares while 640 reduced holdings. 132 funds opened positions while 462 raised stakes. 1.06 billion shares or 1.89% more from 1.04 billion shares in 2017Q2 were reported. Ferguson Wellman Capital Mgmt has 696,618 shares for 2.24% of their portfolio. Long Road Counsel holds 0.82% or 12,994 shares. Baxter Bros owns 2,499 shares for 0.06% of their portfolio. Fidelity Natl Fincl Inc holds 207,950 shares or 4.05% of its portfolio. Mastrapasqua Asset Management reported 0.23% stake. Badgley Phelps & Bell Incorporated stated it has 3,609 shares or 0.02% of all its holdings. Cheviot Value Mgmt Limited Company reported 2.94% stake. Orrstown Fincl Inc holds 0.11% in AbbVie Inc. (NYSE:ABBV) or 1,105 shares. Opus Inv Management has invested 1.32% in AbbVie Inc. (NYSE:ABBV). Whittier Trust Co stated it has 238,745 shares. Agf Invests reported 1.46% of its portfolio in AbbVie Inc. (NYSE:ABBV). Hall Laurie J Trustee holds 2.89% or 52,185 shares. Chase Invest Counsel Corporation holds 2,310 shares. The New York-based Blackrock Inc has invested 0.44% in AbbVie Inc. (NYSE:ABBV). 9,152 are held by Frontier Inv Management.

Analysts await AbbVie Inc. (NYSE:ABBV) to report earnings on April, 26. They expect $1.78 earnings per share, up 39.06% or $0.50 from last year’s $1.28 per share. ABBV’s profit will be $2.83B for 15.97 P/E if the $1.78 EPS becomes a reality. After $1.48 actual earnings per share reported by AbbVie Inc. for the previous quarter, Wall Street now forecasts 20.27% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News